IP Library Granted Patent US 9,176,146
Granted Patent B2
US 9,176,146 · App. 12/534,571 · Granted Nov 3, 2015

Methods of treating autism spectrum disorders and compositions for same

Inventor: Theoharis C. Theoharides (Brookline, MA)
Assignee: Theta Biomedical Consulting & Development Co., Inc.
G01N33/6893A61K31/00A61K31/352A61K31/451A61K31/4545A61K31/495A61K31/519A61K31/55A61K36/63A61K45/06G01N2333/5412G01N2800/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,176,146
App. No.
12/534,571
Granted
Nov 3, 2015
Kind
B2
Abstract

Disclosed are compositions that inhibit brain blood vessel leakage, compositions for treating autism spectrum disorders, methods of treating autism spectrum disorders, and methods of screening for an autism spectrum disorder.

Claims (15)

1. A method of treating an autism spectrum disorder, comprising administering to a subject in need thereof an effective amount of a composition comprising one or more flavonoids, wherein the one or more flavonoids are present in an amount of 10-3,000 mg per tablet or capsule and the flavonoids comprise luteolin, and optionally, a serotonin blocker, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antipsychotic agent, a heavy metal chelator, and olive kernel extract and, wherein the composition inhibits brain blood vessel leakage.

2. The method of claim 1 , wherein the autism spectrum disorder is autism.

3. The method of claim 1 , wherein the autism spectrum disorder is Asperger's disorder.

4. The method of claim 1 , wherein the autism spectrum disorder is Rett syndrome.

5. The method of claim 1 , wherein one of the one or more flavonoids is apigenin, astragaline, (−)-epigallocatechin-3 gallate, genistein, hesperetin, hesperidin, kaempferol, myricetin, quercetin, or rutin.

6. The method of claim 1 , wherein the serotonin blocker is azatadine or cyproheptadine.

7. The method of claim 1 , wherein the histamine-1 receptor antagonist is azelastine, azatadine, hydroxyzine, merelastine, or rupatadine.

8. The method of claim 1 , wherein the histamine-3 receptor agonist is R(−)-α-methyl histamine, N α -methyl histamine, N τ -methyl histamine, α-N α -dethylhistamine, α,β-dimethyl histamine, N α -methyl-α-(dimethyl)histamine, N α -methyl-α-(chloromethyl)histamine, or α,β-difluoro-N α -(fluoromethyl)histamine.

9. The method of claim 1 wherein the antipsychotic agent is risperidone.

10. The method of claim 1 wherein the heavy metal chelator is meso-2,3-dimercaptosuccinic acid.

11. The method of claim 1 , wherein the composition is administered by oral or parenteral routes.

12. A method of treating an autism spectrum disorder, comprising administering to a subject in need thereof an effective amount of a composition comprising one or more flavonoids, wherein the one or more flavonoids are present in an amount of 10-3,000 mg per tablet or capsule and the flavonoids comprise luteolin and optionally, a serotonin blocker, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antipsychotic agent, a heavy metal chelator, and olive kernel extract.

13. The method of claim 12 , wherein the autism spectrum disorder is autism.

14. The method of claim 12 , wherein the composition further comprises one or more of apigenin, astragaline, (−)-epigallocatechin-3 gallate, genistein, hesperetin, hesperidin, kaempferol, or myricetin.

15. The method of claim 12 , wherein the composition inhibits brain blood vessel leakage.

Assignments (2)
MERGER Recorded Apr 12, 2022
From: THETA BIOMEDICAL CONSULTING AND DEVELOPMENT CO., INC.
To: THETA BIOMEDICAL CONSULTING AND DEVELOPMENT, LLC
Reel/Frame 060005/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2009
From: THEOHARIDES, THEOHARIS C.
To: THETA BIOMEDICAL CONSULTING & DEVELOPMENT CO., INC.
Reel/Frame 023272/0281 →
Continuity (1)
Related Publication 20110027397A1 · Feb 3, 2011